AP2014007899A0 - 2-Amino, 6-phenyl substituted pyrido [2,3-D] pyrimidine derivatives useful as RAF kinase inhibitors - Google Patents

2-Amino, 6-phenyl substituted pyrido [2,3-D] pyrimidine derivatives useful as RAF kinase inhibitors

Info

Publication number
AP2014007899A0
AP2014007899A0 AP2014007899A AP2014007899A AP2014007899A0 AP 2014007899 A0 AP2014007899 A0 AP 2014007899A0 AP 2014007899 A AP2014007899 A AP 2014007899A AP 2014007899 A AP2014007899 A AP 2014007899A AP 2014007899 A0 AP2014007899 A0 AP 2014007899A0
Authority
AP
ARIPO
Prior art keywords
amino
kinase inhibitors
phenyl substituted
pyrimidine derivatives
raf kinase
Prior art date
Application number
AP2014007899A
Other languages
English (en)
Inventor
Matthew Carl Allgeier
Michael D Kaufman
Daniel L Flynn
Original Assignee
Lilly Co Eli
Deciphera Pharmaceuticals Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47884613&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AP2014007899(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli, Deciphera Pharmaceuticals Llc filed Critical Lilly Co Eli
Publication of AP2014007899A0 publication Critical patent/AP2014007899A0/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
AP2014007899A 2012-03-07 2013-03-05 2-Amino, 6-phenyl substituted pyrido [2,3-D] pyrimidine derivatives useful as RAF kinase inhibitors AP2014007899A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261607702P 2012-03-07 2012-03-07
PCT/US2013/029084 WO2013134243A1 (en) 2012-03-07 2013-03-05 2-amino, 6-phenyl substituted pyrido [2, 3 - d] pyrimidine derivatives useful as raf kinase inhibitors

Publications (1)

Publication Number Publication Date
AP2014007899A0 true AP2014007899A0 (en) 2014-08-31

Family

ID=47884613

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2014007899A AP2014007899A0 (en) 2012-03-07 2013-03-05 2-Amino, 6-phenyl substituted pyrido [2,3-D] pyrimidine derivatives useful as RAF kinase inhibitors

Country Status (39)

Country Link
US (2) US9334267B2 (lt)
EP (1) EP2850082B1 (lt)
JP (1) JP2015509536A (lt)
KR (1) KR20140129087A (lt)
CN (1) CN104302646B (lt)
AP (1) AP2014007899A0 (lt)
AR (1) AR090151A1 (lt)
AU (1) AU2013230146B2 (lt)
BR (1) BR112014018528A8 (lt)
CA (1) CA2863673A1 (lt)
CL (1) CL2014002220A1 (lt)
CO (1) CO7010837A2 (lt)
CR (1) CR20140378A (lt)
CY (1) CY1117846T1 (lt)
DK (1) DK2850082T3 (lt)
DO (1) DOP2014000200A (lt)
EA (1) EA024824B1 (lt)
EC (1) ECSP14017584A (lt)
ES (1) ES2584387T3 (lt)
HK (1) HK1202541A1 (lt)
HR (1) HRP20160654T1 (lt)
HU (1) HUE028095T2 (lt)
IL (1) IL234052A (lt)
IN (1) IN2014MN01575A (lt)
LT (1) LT2850082T (lt)
MA (1) MA37316B1 (lt)
ME (1) ME02423B (lt)
MX (1) MX2014010701A (lt)
NZ (1) NZ627454A (lt)
PE (1) PE20142338A1 (lt)
PH (1) PH12014501986A1 (lt)
PT (1) PT2850082T (lt)
RS (1) RS54840B1 (lt)
SG (1) SG11201404969YA (lt)
SI (1) SI2850082T1 (lt)
TN (1) TN2014000375A1 (lt)
TW (1) TW201348233A (lt)
UA (1) UA112340C2 (lt)
WO (2) WO2013134252A1 (lt)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR090151A1 (es) * 2012-03-07 2014-10-22 Lilly Co Eli Compuestos inhibidores de raf
US8461179B1 (en) 2012-06-07 2013-06-11 Deciphera Pharmaceuticals, Llc Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
TWI704151B (zh) 2014-12-22 2020-09-11 美商美國禮來大藥廠 Erk抑制劑
AU2017279046B2 (en) * 2016-06-10 2020-07-02 Novartis Ag Therapeutic uses of a c-Raf inhibitor
EP3558979B1 (en) 2016-12-22 2021-02-17 Boehringer Ingelheim International GmbH Novel benzylamino substituted quinazolines and derivatives as sos1 inhibitors
WO2018200981A1 (en) * 2017-04-28 2018-11-01 Quartz Therapeutics, Inc. Raf-degrading conjugate compounds
MX2020006438A (es) 2017-12-21 2020-09-17 Boehringer Ingelheim Int Nuevas piridopirimidinonas sustituidas con bencilamino y derivados como inhibidores de sos1.
JP7161849B2 (ja) * 2018-01-24 2022-10-27 株式会社クラレ 第一級アミンの製造方法
JP2021512105A (ja) 2018-01-31 2021-05-13 デシフェラ・ファーマシューティカルズ,エルエルシー 消化管間質腫瘍の治療のための併用療法
JP2022500385A (ja) 2018-09-10 2022-01-04 ミラティ セラピューティクス, インコーポレイテッド 組み合わせ療法
SI3902547T1 (sl) 2018-12-28 2024-02-29 Deciphera Pharmaceuticals, Llc Inhibitorji CSF1R za uporabo pri zdravljenju raka
DK3921030T3 (da) 2019-02-06 2024-01-02 Lilly Co Eli 1-((2-(2,2,2-trifluoroethoxy)pyridin-4-yl)methyl)urea-derivater som kcnq-potentiatorer
US10927111B2 (en) 2019-05-03 2021-02-23 Kinnate Biopharma Inc. Inhibitors of RAF kinases
TW202108574A (zh) 2019-05-10 2021-03-01 美商迪賽孚爾製藥有限公司 雜芳基胺基嘧啶醯胺自噬抑制劑及其使用方法
US11530206B2 (en) 2019-05-10 2022-12-20 Deciphera Pharmaceuticals, Llc Phenylaminopyrimidine amide autophagy inhibitors and methods of use thereof
KR20220024605A (ko) 2019-06-17 2022-03-03 데시페라 파마슈티칼스, 엘엘씨. 아미노피리미딘 아미드 자가포식 억제제 및 이의 사용 방법
BR112022002609A2 (pt) 2019-08-12 2022-08-09 Deciphera Pharmaceuticals Llc Métodos de tratamento de tumores estromais gastrointestinais
WO2021030405A1 (en) 2019-08-12 2021-02-18 Deciphera Pharmaceuticals, Llc Ripretinib for treating gastrointestinal stromal tumors
IL293864A (en) 2019-12-30 2022-08-01 Deciphera Pharmaceuticals Llc Preparations of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3- phenylurea
SI4084778T1 (sl) 2019-12-30 2024-01-31 Deciphera Pharmaceuticals, Llc Formulacije inhibitorja amorfne kinaze in načini njihove uporabe
CR20220614A (es) 2020-06-02 2023-05-08 Univ Vanderbilt 2-amino-3-cianotiofenos anulados y derivados para el tratamiento del cáncer
WO2022060996A1 (en) 2020-09-18 2022-03-24 Kinnate Biopharma Inc. Inhibitors of raf kinases
WO2022081469A1 (en) 2020-10-12 2022-04-21 Kinnate Biopharma Inc. Inhibitors of raf kinases
EP4237423A1 (en) 2020-11-02 2023-09-06 Boehringer Ingelheim International GmbH Substituted 1h-pyrazolo[4,3-c]pyridines and derivatives as egfr inhibitors
WO2022109001A1 (en) 2020-11-18 2022-05-27 Deciphera Pharmaceuticals, Llc Gcn2 and perk kinase inhibitors and methods of use thereof
EP4267250A1 (en) 2020-12-22 2023-11-01 Qilu Regor Therapeutics Inc. Sos1 inhibitors and uses thereof
KR20240000534A (ko) 2021-04-23 2024-01-02 킨네이트 바이오파마 인크. Raf 억제제를 이용하는 암의 치료
US12065427B2 (en) 2021-04-29 2024-08-20 Boehringer Ingelheim International Gmbh Heterocyclic compounds capable of activating STING
WO2023099620A1 (en) 2021-12-01 2023-06-08 Boehringer Ingelheim International Gmbh Kras degrading compounds comprising annulated 2-amino-3-cyano thiophenes
WO2023099612A1 (en) 2021-12-01 2023-06-08 Boehringer Ingelheim International Gmbh Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
WO2023099592A1 (en) 2021-12-01 2023-06-08 Boehringer Ingelheim International Gmbh Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
WO2023099623A1 (en) 2021-12-01 2023-06-08 Boehringer Ingelheim International Gmbh Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
PE20241356A1 (es) 2021-12-01 2024-07-03 Boehringer Ingelheim Int Gmbh Tiofenos 2-amino-3-ciano anulados y derivados para el tratamiento del cancer
WO2023099608A1 (en) 2021-12-01 2023-06-08 Boehringer Ingelheim International Gmbh Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
US20230357179A1 (en) 2021-12-09 2023-11-09 Deciphera Pharmaceuticals, Llc Raf kinase inhibitors and methods of use thereof
WO2023118250A1 (en) 2021-12-23 2023-06-29 Boehringer Ingelheim International Gmbh 8-aza quinazolines as brain-penetrant sos1-inhibitors
WO2023173017A1 (en) * 2022-03-09 2023-09-14 Blossomhill Therapeutics, Inc. Kras inhibitors for treating disease
US11779572B1 (en) 2022-09-02 2023-10-10 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors
WO2024089006A1 (en) 2022-10-26 2024-05-02 Boehringer Ingelheim International Gmbh Heterocyclic compounds capable of activating sting
WO2024089008A1 (en) 2022-10-26 2024-05-02 Boehringer Ingelheim International Gmbh Heterocyclic compounds capable of activating sting
WO2024088991A1 (en) 2022-10-26 2024-05-02 Boehringer Ingelheim International Gmbh Heterocyclic compounds capable of activating sting

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1447405A4 (en) * 2001-10-17 2005-01-12 Kirin Brewery QUINOLINE OR QUINAZOLINE DERIVATIVES INHIBITING THE AUTOPHOSPHORYLATION OF FIBROBLAST GROWTH FACTOR RECEPTORS
EP1566379A4 (en) * 2002-10-29 2005-11-09 Kirin Brewery QUINOLINE AND QUINAZOLINE DERIVATIVES INHIBITING THE AUTOPHOSPHORYLATION OF FLT3 AND MEDICAL COMPOSITIONS CONTAINING SAME
US20070054916A1 (en) 2004-10-01 2007-03-08 Amgen Inc. Aryl nitrogen-containing bicyclic compounds and methods of use
US8188113B2 (en) * 2006-09-14 2012-05-29 Deciphera Pharmaceuticals, Inc. Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
US7897762B2 (en) 2006-09-14 2011-03-01 Deciphera Pharmaceuticals, Llc Kinase inhibitors useful for the treatment of proliferative diseases
US8901137B2 (en) * 2010-02-09 2014-12-02 Exelixis, Inc. Methods of treating cancer using pyridopyrimidinone inhibitors of PI3K and mTOR in combination with autophagy inhibitors
AR090151A1 (es) * 2012-03-07 2014-10-22 Lilly Co Eli Compuestos inhibidores de raf

Also Published As

Publication number Publication date
MA37316B1 (fr) 2017-03-31
PH12014501986B1 (en) 2014-11-24
TW201348233A (zh) 2013-12-01
TN2014000375A1 (en) 2015-12-21
PT2850082T (pt) 2016-07-15
AU2013230146B2 (en) 2015-09-10
HUE028095T2 (en) 2016-11-28
DOP2014000200A (es) 2014-10-15
HK1202541A1 (en) 2015-10-02
BR112014018528A2 (lt) 2017-06-20
MA37316A1 (fr) 2016-06-30
SG11201404969YA (en) 2014-10-30
CR20140378A (es) 2014-11-27
US8741911B2 (en) 2014-06-03
EA201491456A1 (ru) 2014-12-30
NZ627454A (en) 2016-09-30
WO2013134243A1 (en) 2013-09-12
LT2850082T (lt) 2016-09-12
UA112340C2 (uk) 2016-08-25
PH12014501986A1 (en) 2014-11-24
CL2014002220A1 (es) 2015-06-05
CN104302646B (zh) 2016-05-04
JP2015509536A (ja) 2015-03-30
HRP20160654T1 (hr) 2016-07-01
IN2014MN01575A (lt) 2015-05-08
AU2013230146A1 (en) 2014-08-14
US20130252977A1 (en) 2013-09-26
IL234052A (en) 2016-05-31
BR112014018528A8 (pt) 2017-07-11
SI2850082T1 (sl) 2016-07-29
RS54840B1 (sr) 2016-10-31
WO2013134252A1 (en) 2013-09-12
AR090151A1 (es) 2014-10-22
ES2584387T3 (es) 2016-09-27
CA2863673A1 (en) 2013-09-12
EP2850082B1 (en) 2016-05-18
CY1117846T1 (el) 2017-05-17
PE20142338A1 (es) 2015-01-10
MX2014010701A (es) 2015-03-10
DK2850082T3 (en) 2016-08-15
EA024824B1 (ru) 2016-10-31
CN104302646A (zh) 2015-01-21
ECSP14017584A (es) 2016-01-29
EP2850082A1 (en) 2015-03-25
CO7010837A2 (es) 2014-07-31
ME02423B (me) 2016-09-20
KR20140129087A (ko) 2014-11-06
US9334267B2 (en) 2016-05-10
US20150119392A1 (en) 2015-04-30

Similar Documents

Publication Publication Date Title
AP2014007899A0 (en) 2-Amino, 6-phenyl substituted pyrido [2,3-D] pyrimidine derivatives useful as RAF kinase inhibitors
HRP20171724T1 (hr) Imidazo[1,2-b]piridazin derivati kao inhibitori kinaze
ZA201307839B (en) Pyrazolo[4,3-d] pyrimidines useful as kinase inhibitors
HK1222659A1 (zh) 吡咯並 嘧啶衍生物,它們的製備方法和它們作爲激酶抑制劑的用途
HRP20190361T1 (hr) Derivati triazolo[4,5-d]pirimidina kao antagonisti cb2 receptora
IL236294A (en) 4– (Converted-Amino) –7 h– Pyrrolo [3–2, d] Pyrimidines as lrrk2 Inhibitors
ZA201505454B (en) Pyrrolo [2, 3 -d]pyrimidine derivatives as inhibitors of janus- related kinases (jak)
HK1200447A1 (en) 1h-pyrrolo[2,3-b] pyridine derivatives and their use as kinase inhibitors 1h-[2,3-b]
IL242162B (en) Pyrrolo [2, 3 –d] pyrimidine derivatives as 2cb receptor agonists
ZA201507389B (en) 2-phenyl or 2-hetaryl imidazol[1,2-a]pyridine derivatives
EP2970278A4 (en) Pyrrolo [2,3] PYRIDINE KINASE INHIBITORS CDK9-
SG11201408816QA (en) 3-(PYRAZOLYL)-1H-PYRROLO[2,3-b]PYRIDINE DERIVATIVES AS KINASE INHIBITORS